NEW YORK (GenomeWeb) – Molecular diagnostics firm Kew and Japanese life science product manufacturer Denka have entered into a joint venture to provide genomic profiling to cancer patients in Japan.

The new joint venture, Denka-Kew Genomics (DKGX), plans to open a commercial clinical laboratory in Tokyo in the first half of 2017. Kew will provide DKGX with a license to its cancer sequencing platform, CancerPlex, a 400-gene next-generation sequencing-based cancer panel that aims to match patients' tumor molecular profiles to drugs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.

Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.

La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.

In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.

Sponsored by

This webinar will discuss the advantages of a multiple-biomarker-based approach for immune profiling that provides clinicians with a rational means to consider approved immunotherapies or assign patients to immunotherapy clinical trials.

Sponsored by

This webinar will discuss the benefits of using unique molecular indices to overcome some challenges associated with next-generation sequencing panels.

Sponsored by

This webinar will discuss the role of a newly discovered, brain-enriched form of non-CpG DNA methylation in neural development and disease.

Sponsored by
Agilent Technologies

This webinar will discuss a molecular barcode-based error correction method that enables combined mutation detection and DNA copy number profiling through circulating tumor DNA sequencing.